Cum enim medicamento metabolizing enzyme activities paulatim pauci numero cum prolongationem in vitro incubation tempus, traditional in vitro metabolismi exempla sunt limitations ut brevi incubitu est 2.5 μl metabolicos et altum est Clint est Low (Metabolized Metabolized[1]. Interea,hepatocytes have magis enzymes requiritur oxidatio, reductionem, hydrolysis et diminorization profectae comparari admicrosomes iecurEt in Vitro Systems, multi novae exempla tendunt ad optimized fundatur inhepatocyte Ratio et adhuc imo in vivo environment ad prolongare retention of enzyme operatio inhepatocyteS, et in incubitu temporis providet facultatem ad monitor sufficientem metabolicae transmutatio tardus metabolizing medicinae[1,2].
In view of this, IPHASE, as a leader in biological reagents for in vitro research, has pioneered the HepatoMax™ System and HepatoCon™ Media System based on the study of adherent primary hepatocytes and stromal cells of various genera, including human, monkey, canine, rat, and mouse, etc. The HepatoMax™ System and HepatoCon™ Media System were developed using the adherent primariahepatocyteS vel exemplum, et utrumque systems erigentur ad determinationem actus et metabolicae stabilitatem specifica enzyme genera et incremento in responsione valorem de metabolitarum de medicamento tolbutamide ad X diebus et VII diebus ut cognoscere systems. Metabolite incremento responsum valorem ad X diebus et operatio et metabolicae stabilitas specifica enzyme ad VII dies sunt determinari ad convalidandum systems.
- (I) Duo ratione medicamine huiusmodi culturae processuum sunt, ut sequitur:
Iphase - ™ HepatomaxEst Co - Culture ratio gelida muratas primaria humana hepatocytes et stromal cellulis. Primary human hepatocytes were resuscitated and incubated with stromal cells in HepatoP™ medium for 3 days to start the drug administration assay, and the metabolism of the drug was carried out in serum-free HepatoDo™ medium, which was replenished only with the drug without changing the medium. A summa IV: LXXII, CLXVIII et CCXL horas post medicamento administratione, ad valorem additae medicamento metabolitarum determinari ad analysis.
Iphase - ™ HepatoconIn alia manu, est ratio pro culturing gelida adhaerens primaria Hepatocytes in Hepatocon ™ medium. Post resuscitanding primaria hominumhepatocyteS, in medicamento administrationis Assay post III diebus Culture in Hepatocon ™ medium solum, et subsequent tempus administrationis, culturae system et in Asay Methodology erant idem quod illi de Hepatomax ™ ratio.
Interea ad curare accurate et rigorem eventus, iPhase perfecerunt medium imperium (cellulam - liberum) et stromal cellula simul cum tribus replications et eventus ostendit quodIphase - ™ Hepatomax etIphase - ™ Hepatocon Systems produci fortis apicem metabolite responsum a die III deinceps, et quod tam ostendit fortis metabolicae turnover.
- (II) medicamento metabolismus est maxime dependens in HepatocyteCYP450Enzyme ratio et operatio potest metiri melius examine.
InIphase - ™ Hepatomax etIphase - ™ Hepatocon Systems habere bonum applicability.
Iphase extruxerat quattuor genera medii imperium (non cellulis), hepatomax ™ Hepatocon ™ et stromal cellulis. Using Wall - Adherent Prima Humanumhepatocytes sicut in exemplum, in metabolite incremento valuesCYP1A2, CYP2B6etCYP3A4sunt verificatur hodie 0, III et VII posthepatocyteRecuperatio in III diebus usura finasteride, Bupropion et Midazolam ut subiecta, respective. Metabolite incremento values ostendit ut tumIphase - ™ Hepatomax etIphase - ™ Hepatocon Systems ostendit activae enzyme actio per diem VII, constanter promovendi normalis medicamento metabolism.
- (III) In addition ad sanationem de enzyme operatio, bonum metabolicae stabilitas est etiam momenti et indispensable gradus in convalidando ad utilitatem in Vitro exempla.
Iphase erexit tres genera Hepatomax ™, Hepatocon ™ et stromal cellulis determinare ad metabolicae stabilitatem Tolbutimide super a tempus LXXX horis usura adhaerens primaria Human Hepatocysticum quod per primariahepatocytes, et eventus ostendit quod tamIphase - ™ Hepatomax etIphase - ™ Hepatocon Systems et ostendit robust metabolicae alvi operatio in longissimum valorem de asay est.
In summary, Iphase, ut princeps in vitro bio - Reagents, habet developedIphase Hepatomax ™ etIphase Hepatocon ™ In Vitro Models secundum Wall - applicari prima humana, simia, canine, rat et mushepatocyteS et stromal cellulis de variis genera, cum optimum metabolic turnover, activae enzyme actiones et potens metabolicae alvi activities, quod offer novum electiones pro nostra customers ut develop humilis - alvi pharmaca inventa est ad cognitionem? InIphase Hepatomax ™ etIphase Hepatocon ™ In Vitro exempla offerre optimum metabolicae turnover rates, activae enzyme activities et fortes metabolis alvi activities, providing novi options ad customers ut develop low - alvi pharmaca, et quod est momenti socium in medicamento inventa!
Reference:
[I] 阮婷婷, 鞠武建, 熊海伟, 等. 低清除率药物的代谢稳定性预测模型研究进展 [J]. 中国药科大学学报, MMXIX (II) CLII - CLX.
[II] Di l, Trapa P, Obach R S, et al. A novae Nullam Method ad determinandum humilis - alvi values [J]. Medicamento metabolismus et dispositio, MMXII, XL (IX) MDCCCLX - MDCCCLXV.
Post tempus: MMXXIV - VII - 17:20:41 XIX